MX9601033A - Nanosuspensiones para administracion intravenosa. - Google Patents
Nanosuspensiones para administracion intravenosa.Info
- Publication number
- MX9601033A MX9601033A MX9601033A MX9601033A MX9601033A MX 9601033 A MX9601033 A MX 9601033A MX 9601033 A MX9601033 A MX 9601033A MX 9601033 A MX9601033 A MX 9601033A MX 9601033 A MX9601033 A MX 9601033A
- Authority
- MX
- Mexico
- Prior art keywords
- staurousporine
- intravenous administration
- benzoyl
- nanosuspensions
- water
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/08—Logistics, e.g. warehousing, loading or distribution; Inventory or stock management
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
- G06K19/06—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
- G06K19/067—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components
- G06K19/07—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips
- G06K19/0723—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips the record carrier comprising an arrangement for non-contact communication, e.g. wireless communication circuits on transponder cards, non-contact smart cards or RFIDs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Business, Economics & Management (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Economics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Biophysics (AREA)
- Marketing (AREA)
- Heart & Thoracic Surgery (AREA)
- Human Resources & Organizations (AREA)
- Entrepreneurship & Innovation (AREA)
- Operations Research (AREA)
- General Business, Economics & Management (AREA)
- Tourism & Hospitality (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Strategic Management (AREA)
- Development Economics (AREA)
- Cardiology (AREA)
- Quality & Reliability (AREA)
Abstract
La presente invencion se refiere a una composicion farmacéutica para la administracion intravenosa del derivado de estaurosporina escasamente soluble N-benzoil-estaurosporina. La composicion comprende los siguientes componentes preferidos. a) el agente terapéutico N-benzoil-estaurosporina; b) un copolímero de bloque de polioxietileno/polioxipropileno; c) etanol y agua como líquidos portadores; y d) lecitina purificada de frijol de soya y e) como excipientes solubles en agua, glicerol y sorbitol.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH804/95 | 1995-03-21 | ||
| CH00804/95 | 1995-03-21 | ||
| CH80495 | 1995-03-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX9601033A true MX9601033A (es) | 1997-09-30 |
| MXPA96001033A MXPA96001033A (es) | 1998-07-03 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9601032A (es) | Vehiculos farmaceuticos para nanosuspensiones. | |
| PL325825A1 (en) | Microemulsion for use as a carrier for administering active compounds | |
| JO3404B1 (ar) | تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين | |
| MX9709094A (es) | Formulaciones farmaceuticas de derivados muy lipofilos de la comptotecina. | |
| UA88270C2 (ru) | Фармацевтический препарат и его применение для профилактики удара, диабета | |
| IT1270594B (it) | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida | |
| ES2007100A6 (es) | Procedimiento para la obtencion de un sistema terapeutico oral a base de carbamazepina. | |
| HUP0004383A2 (hu) | Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény | |
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| GEP20053595B (en) | Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment | |
| IS1907B (is) | Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm | |
| DK0600079T3 (da) | Oral 1alpha-hydroxyprævitamin D | |
| DK0869808T3 (da) | Anvendelse af Glu-Trp-dipeptider til fremstilling af et lægemiddel til behandling af forskellige tilstande, der involverer neovaskularisation | |
| DE59102210D1 (de) | Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus. | |
| TR200103613T2 (tr) | Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler. | |
| UA41446C2 (uk) | Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі | |
| CA2215327A1 (en) | Formulations for lipophilic compounds | |
| DE60019334D1 (de) | Antivirale arznei | |
| RU95105973A (ru) | Способ снижения тяжести токсоплазмоза, фармацевтическая композиция, применение производных рифамицина для получения лекарственных препаратов для лечения токсоплазмоза | |
| KR970025615A (ko) | 암 전이 억제제 | |
| IL118162A0 (en) | Nanoparticles for oral administration of pharmaceutical agents of low solubility | |
| ATE213633T1 (de) | Lamotrigin haltiges arzneimittel | |
| WO1999033450A3 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| DE69928806D1 (de) | (-)-pseudoephedrin als sympathomimetisches arzneimittel | |
| TW349865B (en) | Therapeutic agent for hemorrhoidal diseases |